GR3030293T3 - Angiotensin ii receptor blocking compositions - Google Patents

Angiotensin ii receptor blocking compositions

Info

Publication number
GR3030293T3
GR3030293T3 GR990401379T GR990401379T GR3030293T3 GR 3030293 T3 GR3030293 T3 GR 3030293T3 GR 990401379 T GR990401379 T GR 990401379T GR 990401379 T GR990401379 T GR 990401379T GR 3030293 T3 GR3030293 T3 GR 3030293T3
Authority
GR
Greece
Prior art keywords
angiotensin
receptor blocking
blocking compositions
blocker
compositions
Prior art date
Application number
GR990401379T
Other languages
English (en)
Inventor
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of GR3030293T3 publication Critical patent/GR3030293T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR990401379T 1990-12-14 1999-05-20 Angiotensin ii receptor blocking compositions GR3030293T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62880790A 1990-12-14 1990-12-14
PCT/US1991/009362 WO1992010097A1 (en) 1990-12-14 1991-12-13 Angiotensin ii receptor blocking compositions

Publications (1)

Publication Number Publication Date
GR3030293T3 true GR3030293T3 (en) 1999-09-30

Family

ID=24520386

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401379T GR3030293T3 (en) 1990-12-14 1999-05-20 Angiotensin ii receptor blocking compositions

Country Status (14)

Country Link
EP (1) EP0565634B1 (el)
JP (1) JP3398379B2 (el)
KR (1) KR100222252B1 (el)
AT (1) ATE177634T1 (el)
AU (1) AU656551B2 (el)
CA (1) CA2098176C (el)
DE (2) DE69131021T2 (el)
DK (1) DK0565634T3 (el)
ES (1) ES2130170T3 (el)
GR (1) GR3030293T3 (el)
HK (1) HK1012209A1 (el)
LU (1) LU91234I2 (el)
NL (1) NL300115I2 (el)
WO (1) WO1992010097A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
PT914158E (pt) * 1996-04-05 2002-11-29 Takeda Chemical Industries Ltd Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
EP0910375B1 (en) * 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
PL198875B1 (pl) * 1997-08-06 2008-07-31 Smithkline Beecham Corp Kompleks kwasu (E)-α-[2-n-butylo-1-[(4-karboksyfenylo)metylo]-1H-imidazol-5-ilo]metyleno-2-tiofenopropionowego arginylu, sposób jego wytwarzania, kompozycja farmaceutyczna zawierajaca ten związek oraz jego zastosowanie
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
CA2338256C (en) * 1998-07-20 2008-09-23 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AR040017A1 (es) * 2002-05-17 2005-03-09 Novartis Ag Combinacion de compuestos organicos
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
CN1938021A (zh) * 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
KR20070006774A (ko) * 2004-03-17 2007-01-11 노파르티스 아게 치료에서 레닌 억제제의 용도
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
EP2079452A4 (en) * 2006-10-30 2010-01-06 Hanall Pharmaceutical Co Ltd CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THIAZIDS AND BLOCKERS OF ANGIOTENSIN II RECEPTORS
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CN101990428A (zh) 2008-04-10 2011-03-23 韩兀生物制药株式会社 药物制剂
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX2014013320A (es) 2012-05-07 2015-08-10 Bayer Pharma AG Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
ATE250587T1 (de) * 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
DE69131021T2 (de) 1999-08-12
EP0565634A4 (en) 1996-04-17
KR100222252B1 (ko) 1999-10-01
JPH06503834A (ja) 1994-04-28
NL300115I1 (nl) 2003-05-01
DE69131021D1 (de) 1999-04-22
EP0565634B1 (en) 1999-03-17
CA2098176C (en) 2006-12-12
ATE177634T1 (de) 1999-04-15
KR930702895A (ko) 1993-11-29
AU9178291A (en) 1992-07-08
ES2130170T3 (es) 1999-07-01
JP3398379B2 (ja) 2003-04-21
WO1992010097A1 (en) 1992-06-25
HK1012209A1 (en) 1999-07-30
AU656551B2 (en) 1995-02-09
DK0565634T3 (da) 1999-09-27
NL300115I2 (nl) 2003-09-01
DE10399008I1 (de) 2006-06-08
CA2098176A1 (en) 1992-06-14
EP0565634A1 (en) 1993-10-20
LU91234I2 (fr) 2006-06-12

Similar Documents

Publication Publication Date Title
HK1012209A1 (en) Angiotensin ii receptor blocking compositions
RU2012110522A (ru) Гипотензивная комбинация валсартана и блокатора кальциевых каналов
GR3034485T3 (en) Tricyclic substituted hexahydrobenz e]isoindole alpha-1 adrenergic antagonists
IL122242A0 (en) Combination of angiotensin II receptor and epoxy-steroidal aldosterone receptor antagonist
BG102976A (en) Method for the preparation of drospyrenon (6 beta,7 beta: 15 beta,16 beta - dimethylene-3-oxo-17 alpha -pregn-4-ene-21,17-carbolacton, drsp)as well as 7 alpha-(3-hydroxy-1-propyl)-(6 beta,7 beta: 15 beta,16 beta -dirmethylene-5 beta-androstan-3 beta,5,17 beta -triol (zk 92836) and (6 beta,7 beta: 15 beta,16 beta - dimethylene-5 beta-hydroxy-3-oxo-17 alpha -androstan-21, 17-carbolacton (90965) as intermediate compounds of the method
EP0827293A3 (en) Method of synchronizing satellite switched CDMA communication system
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
EP0956044A4 (en) USES OF A CHEMOKIN RECEPTOR TO INHIBIT HIV-1 INFECTION
EP1009435A4 (en) METHOD FOR PREVENTING HIV INFECTION FROM CD4? + CELLS
CA2342454A1 (en) Spread spectrum interference canceler system and method
EP0825867A4 (en) N, O-CARBOXYMETHYLCHITOSAN FOR THE PREVENTION OF SURGICAL ADHESIONS
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
IL116406A0 (en) Tricyclic substituted hexahydrobenz (e) isoindole alpha-1 adrenergic antagonists
EP0726072A3 (en) Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
AU8844491A (en) Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
EP1335747A4 (en) COMPOSITION COMPOSITION BLOCKING SODIUM CHANNELS
AU3498795A (en) Method of blocking the sec receptor
AU6187898A (en) Method for preventing or treating low renin hypertension by administering an endothelin antagonist
HK1011285A1 (en) Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2-inhibitor
ES2175437T3 (es) Composicion de enalapril y losartan.
EP0983243A4 (en) NOVEL QUINOLINE- AND NAPHTHALENECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INHIBITING CALPAIN
MX9708557A (es) Nuevo uso farmacologico de los antagonistas del receptor aii.
BG103553A (en) Benzopyranopyrol and benzopyranopyridine alpha-1 adrenergic compounds